
A PRA Expert’s Experience Treating the First Pediatric Patient to Receive CAR T-Cell Therapy
Emily Whitehead was born on May 2nd of 2005, a perfectly healthy baby. When she reached five, her parents noticed bruising on her legs, bleeding…
Emily Whitehead was born on May 2nd of 2005, a perfectly healthy baby. When she reached five, her parents noticed bruising on her legs, bleeding…
Cancer is a leading cause of death worldwide. Despite the lack of a definitive cure for cancer, there are many types of cancer treatments. A…
Learn more about how PRA worked with a sponsor to create higher enrollment rates and more extensive country selection. Discover how they did this by…
As we work our way through October and deeper into autumn, there have been many recent developments in healthcare and clinical research. There’s a…
A case study describing two Phase II, multicenter studies assessing the efficacy and safety of an autologous cellular therapy treatment.
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…
Now that the RACE for Children Act has come into effect, the drug development industry and patients and their families are optimistic—more drugs will…
With fall in the air in the northern hemisphere, it’s also a week full of noteworthy news in clinical development. New research shines a light on…
This strategic relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to…
PRA has partnered with The Leukemia and Lymphoma Society (LLS) on a global precision medicine clinical trial for children with relapsed acute…